Astellas Transfers Luvox Japanese Rights To Abbott
This article was originally published in PharmAsia News
Astellas Pharma Inc. will transfer rights to antidepressant Luvox (fluvoxamine) to Abbott Japan Co., starting April 2012
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.